<DOC>
	<DOCNO>NCT01723735</DOCNO>
	<brief_summary>Primary Objective : To assess pharmacodynamic profile alirocumab ( SAR236553/REGN727 ) administer either alone top ezetimibe fenofibrate , base low-density lipoprotein -cholesterol ( LDL-C ) . Secondary Objectives : - To assess pharmacodynamic profile alirocumab administer either alone top ezetimibe fenofibrate , base lipid parameter . - To assess pharmacokinetic profile alirocumab administer either alone top ezetimibe fenofibrate .</brief_summary>
	<brief_title>Effect Alirocumab ( SAR236553/REGN727 ) Administered Top Ezetimibe Fenofibrate Lipid Profiles Healthy Subjects</brief_title>
	<detailed_description>Total duration study per subject ( exclude screen ) 22 week .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Healthy male /or female subject , age 18 65 year old , LDLC &gt; 130 mg/dL receive lipid lower therapy . Exclusion criterion : Healthy subject history presence clinically relevant illness . Subjects currently take statin , ezetimibe fenofibrate . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>